EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis

Hironobu Kosugiyama, Shuji Asai iD, Kenya Terabe, Tomonori Kobayakawa, Yutaka Yoshioka, Tatsuo Watanabe, Toshihisa Kojima, Yasumori Sobue iD, Takefumi Kato, Takayoshi Fujibayashi, Yuji Hirano, Tsuyoshi Nishiume und 12 weitere

International Journal of Rheumatic Diseases · 2025

DOI: 10.1111/1756-185x.70288 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Rheumatic Diseases, 2025. Verfasst von Hironobu Kosugiyama und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Azetidines, Sulfonamides, Pyrazoles. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To compare the clinical effectiveness of baricitinib and filgotinib in the treatment of rheumatoid arthritis (RA).

Methods

This retrospective study included 101 and 103 consecutive patients treated with baricitinib and filgotinib, respectively, between 2020 and 2023. Drug retention was analyzed using Kaplan–Meier curves, with the log‐rank test for between‐group comparisons. Differences in Clinical Disease Activity Index (CDAI) score from baseline were assessed using paired t ‐tests, and generalized estimating equations were used to compare the treatment groups.

Results

Baseline characteristics were similar between the baricitinib and filgotinib groups. Drug retention rates due to ineffectiveness or adverse events did not differ significantly between the two groups. In the baricitinib group, the estimated mean CDAI score significantly decreased from 17.8 at baseline to 9.1 at 4 weeks, 6.6 at 12 weeks, and 6.3 at 24 weeks ( p < 0.001 for all comparisons). In the filgotinib group, the estimated mean CDAI score significantly decreased from 16.5 at baseline to 7.8 at 4 weeks, 6.2 at 12 weeks, and 6.1 at 24 weeks ( p < 0.001 for all comparisons). No significant differences were observed between the two groups in CDAI score at any time point evaluated, or in the proportion of patients who achieved CDAI remission (CDAI ≤ 2.8) at baseline (7% vs. 5%) and after 4 (23% vs. 21%), 12 (33% vs. 33%), and 24 weeks (33% vs. 37%).

Conclusion

Baricitinib and filgotinib demonstrated comparable drug retention rates and effectiveness in reducing disease activity among patients with RA over a 24‐week follow‐up period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAzetidinesSulfonamidesPyrazolesAntirheumatic AgentsPyridinesHumansMaleFemaleRetrospective StudiesMiddle AgedTreatment OutcomeAgedAdultTime FactorsJanus Kinase InhibitorsPurinesTriazoles

Stichwörter der Autor:innen

Janus kinase inhibitorbaricitinibdrug effectfilgotinibrheumatoid arthritis

Substanzen

baricitinibAzetidinesGLPG0634SulfonamidesPyrazolesAntirheumatic AgentsPyridinesJanus Kinase InhibitorsPurinesTriazoles

Autor:innen und Institutionen

  • Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Department of Rheumatology, Shizuoka Kosei Hospital, Shizuoka, Shizuoka, Japan.
  • Kobayakawa Orthopedic and Rheumatologic Clinic, Shizuoka, Japan.
  • Department of Rheumatology, Handa City Hospital, Handa, Aichi, Japan.
  • Department of Orthopedic Surgery, Daido Hospital, Nagoya, Aichi, Japan.
  • Department of Orthopedic Surgery and Rheumatology, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan.

ORCID-Profile: Shuji Asai, Yasumori Sobue, Yasuhide Kanayama, Mochihito Suzuki, Junya Hasegawa, Nobunori Takahashi

Zitieren

APA

Kosugiyama, H., Asai, S., Terabe, K., Kobayakawa, T., Yoshioka, Y., Watanabe, T., Kojima, T., Sobue, Y., Kato, T., Fujibayashi, T., Hirano, Y., Nishiume, T., Kato, M., Kanayama, Y., Takemoto, T., Hanabayashi, M., Matsubara, H., Suzuki, M., Sato, R., …, & Imagama, S. (2025). Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70288

Vancouver

Kosugiyama H, Asai S, Terabe K, Kobayakawa T, Yoshioka Y, Watanabe T, et al. Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70288

BibTeX
@article{Kosugiyama2025,
  author = {Kosugiyama, Hironobu and Asai, Shuji and Terabe, Kenya and Kobayakawa, Tomonori and Yoshioka, Yutaka and Watanabe, Tatsuo and Kojima, Toshihisa and Sobue, Yasumori and Kato, Takefumi and Fujibayashi, Takayoshi and Hirano, Yuji and Nishiume, Tsuyoshi and Kato, Mihoko and Kanayama, Yasuhide and Takemoto, Toki and Hanabayashi, Masahiro and Matsubara, Hiroyuki and Suzuki, Mochihito and Sato, Ryo and Hasegawa, Junya and Ohno, Yusuke and Sugiura, Takaya and Takahashi, Nobunori and Imagama, Shiro},
  title = {Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis},
  journal = {International Journal of Rheumatic Diseases},
  year = {2025},
  doi = {10.1111/1756-185x.70288}
}
Kostenlos starten →